{"id":"NCT00425308","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.","officialTitle":"A Prospective Multicenter Open-label Randomized Study to Assess Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus Without Calcineurine Inhibitor in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10","primaryCompletion":"2009-05","completion":null,"firstPosted":"2007-01-22","resultsPosted":"2011-04-19","lastUpdate":"2017-03-30"},"enrollment":30,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Renal Transplantation"],"interventions":[{"type":"DRUG","name":"Everolimus + Cyclosporine","otherNames":["Cyclosporine Microemulsion","Neoral"]},{"type":"DRUG","name":"Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)","otherNames":["Myfortic"]},{"type":"DRUG","name":"Steroids","otherNames":[]}],"arms":[{"label":"Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)","type":"ACTIVE_COMPARATOR"},{"label":"Everolimus + Cyclosporine","type":"ACTIVE_COMPARATOR"}],"summary":"Efficacy and safety of 2 groups of treatment: everolimus in association with cyclosporine microemulsion and steroids versus everolimus in association with Enteric-coated Mycophenolate Sodium (EC-MPS) and steroids. The study population consists of patients having taken part in study CRAD001A2420 (NCT00154297) until the end (12 months) and having not prematurely discontinued the immunosuppressive regimen received in this study (everolimus + cyclosporine microemulsion + steroids).","primaryOutcome":{"measure":"Change in Glomerular Filtration Rate Estimated by Iohexol Plasma Clearance 12 Months After Randomization Between the 2 Groups of Patients.","timeFrame":"From Baseline to Month 12","effectByArm":[{"arm":"Cyclosporine","deltaMin":-4.07,"sd":5.03},{"arm":"Enteric-coated Mycophenolate Sodium (EC-MPS)","deltaMin":10.3,"sd":4.84}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":1,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":15},"commonTop":["Oedema peripheral","Anaemia","Aphthous stomatitis","Dyslipidaemia","Diarrhoea"]}}